This bill requires health insurance plans in Maine to cover blood testing for perfluoroalkyl and polyfluoroalkyl substances (PFAS) when a healthcare provider deems it medically necessary based on guidelines from the National Academies of Sciences, Engineering, and Medicine. It prohibits insurers from charging deductibles, copays, or coinsurance for these tests. The requirement applies to all health insurance plans issued or renewed in Maine on or after January 1, 2026. The bill states this coverage does not expand the state's essential health benefits under federal law, as it aligns with existing coverage for outpatient lab services.
LD 163 requires all health insurance plans in Maine covering prescription drugs or outpatient services to fully cover federally approved nonprescription oral hormonal contraceptives and emergency contraceptives without any deductibles, copays, or coinsurance. This applies directly to health insurers and enrollees, eliminating out-of-pocket costs for these specific contraceptives. The bill clarifies that no prescription is needed to obtain these items, and coverage must include supplies for a full 12-month period. It specifically excludes coverage for abortion-inducing drugs. The law updates Maine’s health insurance coverage requirements to align with federal contraceptive approvals.
LD 178 prohibits health insurance plans from requiring patients with advanced metastatic cancer or related symptoms (like severe side effects from cancer or treatment) to try and fail on other drugs before covering an FDA-approved treatment. It applies to health plans that cover these conditions and directly affects patients seeking timely access to necessary medications. The law ensures coverage for FDA-approved drugs that align with medical guidelines and evidence-based practice, eliminating a common step therapy barrier. This change removes delays in accessing approved treatments without altering insurance coverage requirements for other conditions.
This bill allocates $250,000 from the General Fund for each of the 2025-26 and 2026-27 fiscal years to support Maine's free health clinics. The funding will be distributed by the Department of Health and Human Services using a formula based on the number of clients served at each clinic plus a base amount per clinic. It directly affects community health clinics providing services to low-income residents, particularly in underserved areas. The bill is a one-time funding measure with no new policy requirements, solely providing financial support for existing clinic operations.
LD 784 requires Maine health insurance plans to cover specific preventive screenings for first responders (including firefighters, police officers, EMTs, and emergency communications personnel) without denying coverage, requiring prior authorization (except to verify first responder status or for screenings by designated providers), or charging out-of-pocket costs. The screenings include cancer tests linked to job risks, blood tests, age-independent cancer screenings, and tests for inflammation or nutritional deficiencies. This law applies to all health insurance policies issued or renewed on or after January 1, 2027, ensuring first responders can access these preventive services without financial or administrative barriers.
LD 1100 clarifies insurance coverage requirements for prescription drugs treating serious mental illness in Maine. It requires health insurance carriers to approve equivalent nonformulary drugs when formulary drugs for serious mental illness become unavailable due to shortages, covering the period of unavailability. The bill also establishes a process for enrollees to request coverage of clinically appropriate non-covered drugs, with insurers required to respond within 72 hours (or 24 hours for emergencies) and cover the drug for the prescription duration. This directly affects health insurance carriers and enrollees with serious mental illness diagnoses. The bill amends Maine Revised Statutes sections 4304 and 4311 to implement these changes.
This bill requires insurance administrators and pharmacy benefits managers to give plan sponsors (like employers or unions that manage health coverage) full ownership of claims data from their contracts. It mandates that administrators provide specific data - including itemized bills, medical records for high-cost claims over $50,000, and payment details - within 20 business days of a request. Plan sponsors gain the right to conduct annual post-payment audits of claims without facing excessive fees or restrictions on audit scope, timing, or auditor choice. The law applies to all new or renewed contracts after January 1, 2026, ensuring transparency in how insurers process and pay claims.
This bill prohibits private equity companies and real estate investment trusts (REITs) from acquiring or increasing ownership or operational control of hospitals in Maine until June 15, 2029. It defines key terms like "operational control" (influencing hospital policies or leadership) and "indirect ownership" to clarify the scope. The moratorium directly affects entities seeking to buy or manage Maine hospitals through private equity or REIT structures. The law will expire automatically on June 15, 2029, without requiring further legislative action.
LD 67 defines "urgent care facility" as a walk-in clinic providing non-life-threatening care, excluding hospital-licensed sites, overnight facilities, and private physician offices. It requires Maine's Department of Health and Human Services to establish licensing standards by July 1, 2026, including a fee between $50 and $500. The standards must cover staffing, care quality, advertising, inspections, complaint handling, and accreditation. These rules directly affect urgent care facilities meeting the defined scope, ensuring minimum operational and safety requirements. The bill creates a regulatory framework without specifying additional funding or penalties.
This bill requires Maine health insurance carriers to report quarterly on denied claims and prior authorizations starting in 2026. Carriers must track the number of denials and list the five most common reasons for both claim denials and prior authorization denials. The Superintendent of Insurance will compile these reports, along with federal data from the Affordable Care Act, into an annual report submitted to the relevant legislative committee by January 31 each year. The committee may then propose new legislation based on the findings to address patterns in insurance denials.
